Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. (ticker: AMHC) is a clinical-stage biopharmaceutical company that completed its business combination with Amplitude Healthcare Acquisition Corporation, a healthcare-focused SPAC sponsored by Amplitude Healthcare Holdings LLC, in 2022. The SPAC conducted its initial public offering in 2021 under the AMHC ticker on Nasdaq, targeting opportunities in the life sciences and healthcare sectors. Jasper Therapeutics focuses on transforming hematopoietic stem cell transplantation through novel conditioning antibody therapies, with its lead program JSP191 targeting the CD117 receptor. The June 2022 8-K filing reflects corporate activity in the period immediately following the de-SPAC transaction. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Jasper Therapeutics and hundreds of other SPAC transactions.